Akira Takashima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Akira Takashima has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Hironori Matsushima
Department of Medical Microbiology and Immunology, University of Toledo College of Medicine, Toledo, OH 43614
8 shared publicationsAkiko Nishibu
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
4 shared publicationsHiroaki Tanaka
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
4 shared publicationsRan Lu
Department of Medical Microbiology and Immunology, University of Toledo College of Medicine, Toledo, OH 43614
3 shared publications- Brant R. Ward
Assistant Professor of Medicine/Virginia Commonwealth University Health System
2 shared publications Mridula Vishwanath
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
2 shared publications
Latest Publications
- 1 February 2015
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 194 (3) , 1211-1224
Neutrophil Priming Occurs in a Sequential Manner and Can Be Visualized in Living Animals by Monitoring IL-1β Promoter Activation
Rapid enhancement of phagocyte functionality is a hallmark of neutrophil priming. GeneChip analyses unveiled elevated CD54, dectin-2, and IL-1β mRNA expression by neutrophils isolated from inflammatory sites. In fact, CD54 and dectin-2 protein expression was detected on neutrophils recovered from skin, peritoneal, and lung inflammation lesions but not on those in bone marrow or peripheral blood. Neutrophils increased CD54 and dectin-2 mRNA during migration in Boyden chambers and acquired CD54 and dectin-2 surface expression after subsequent exposure to GM-CSF. Neutrophils purified from IL-1β promoter-driven DsRed-transgenic mice acquired DsRed signals during cell migration or exposure to GM-CSF. CD54 and dectin-2 were expressed by DsRed+ (but not DsRed−) neutrophils in GM-CSF–supplemented cultures, and neutrophils recovered from inflammatory sites exhibited strong DsRed signals. The dynamic process of neutrophil priming was studied in chemically induced inflammatory skin lesions by monitoring DsRed expression using confocal microscopy. A majority (>80%) of Ly6G+ neutrophils expressed DsRed, and those DsRed+/Ly6G+ cells exhibited crawling motion with a higher velocity compared with their DsRed−/Ly6G+ counterparts. This report unveils motile behaviors of primed neutrophils in living animals. We propose that neutrophil priming occurs in a sequential manner with rapid enhancement of phagocyte functionality, followed by CD54 and dectin-2 mRNA and protein expression, IL-1β promoter activation, and accelerated motility. Not only do these findings provide a new conceptual framework for our understanding of the process of neutrophil priming, they also unveil new insights into the pathophysiology of many inflammatory disorders that are characterized by neutrophil infiltration.
- 1 February 2015
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 194 (3) , 1211-1224
Neutrophil Priming Occurs in a Sequential Manner and Can Be Visualized in Living Animals by Monitoring IL-1β Promoter Activation
Rapid enhancement of phagocyte functionality is a hallmark of neutrophil priming. GeneChip analyses unveiled elevated CD54, dectin-2, and IL-1β mRNA expression by neutrophils isolated from inflammatory sites. In fact, CD54 and dectin-2 protein expression was detected on neutrophils recovered from skin, peritoneal, and lung inflammation lesions but not on those in bone marrow or peripheral blood. Neutrophils increased CD54 and dectin-2 mRNA during migration in Boyden chambers and acquired CD54 and dectin-2 surface expression after subsequent exposure to GM-CSF. Neutrophils purified from IL-1β promoter-driven DsRed-transgenic mice acquired DsRed signals during cell migration or exposure to GM-CSF. CD54 and dectin-2 were expressed by DsRed+ (but not DsRed−) neutrophils in GM-CSF–supplemented cultures, and neutrophils recovered from inflammatory sites exhibited strong DsRed signals. The dynamic process of neutrophil priming was studied in chemically induced inflammatory skin lesions by monitoring DsRed expression using confocal microscopy. A majority (>80%) of Ly6G+ neutrophils expressed DsRed, and those DsRed+/Ly6G+ cells exhibited crawling motion with a higher velocity compared with their DsRed−/Ly6G+ counterparts. This report unveils motile behaviors of primed neutrophils in living animals. We propose that neutrophil priming occurs in a sequential manner with rapid enhancement of phagocyte functionality, followed by CD54 and dectin-2 mRNA and protein expression, IL-1β promoter activation, and accelerated motility. Not only do these findings provide a new conceptual framework for our understanding of the process of neutrophil priming, they also unveil new insights into the pathophysiology of many inflammatory disorders that are characterized by neutrophil infiltration.
- Open Access
- 28 January 2015
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 98 (4) , 489-496
Neutrophil plasticity: acquisition of phenotype and functionality of antigen-presenting cell
Accumulating lines of evidence now demonstrate that neutrophils can participate in adaptive immune responses directly or indirectly. Even more striking is their potential to acquire phenotypic and functional properties that are typically reserved for professional APCs. These newly emerging concepts of neutrophil heterogeneity and plasticity now challenge the classic view of neutrophils as terminally differentiated leukocytes fully committed to phagocyte functionality. Here, we present a brief overview of our current understanding of neutrophil plasticity by focusing on the acquisition of DC-like properties in culture and at sites of inflammation. Human and murine neutrophils acquire surface expression of MHC II, costimulatory molecules, and other surface markers of DCs when cultured in the presence of selected cytokines. The resulting populations also exhibit potent APC activities to present various antigens to T cells. “Unusual” neutrophils expressing DC markers have been detected in inflammatory lesions in human patients and mouse disease models. These findings imply that acquisition of DC-like properties by neutrophils at the sites of inflammation may represent a key process for linking the innate and adaptive arms of immune responses.
- 28 January 2015
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 98 (4) , 489-496
Open AccessNeutrophil plasticity: acquisition of phenotype and functionality of antigen-presenting cell
Accumulating lines of evidence now demonstrate that neutrophils can participate in adaptive immune responses directly or indirectly. Even more striking is their potential to acquire phenotypic and functional properties that are typically reserved for professional APCs. These newly emerging concepts of neutrophil heterogeneity and plasticity now challenge the classic view of neutrophils as terminally differentiated leukocytes fully committed to phagocyte functionality. Here, we present a brief overview of our current understanding of neutrophil plasticity by focusing on the acquisition of DC-like properties in culture and at sites of inflammation. Human and murine neutrophils acquire surface expression of MHC II, costimulatory molecules, and other surface markers of DCs when cultured in the presence of selected cytokines. The resulting populations also exhibit potent APC activities to present various antigens to T cells. “Unusual” neutrophils expressing DC markers have been detected in inflammatory lesions in human patients and mouse disease models. These findings imply that acquisition of DC-like properties by neutrophils at the sites of inflammation may represent a key process for linking the innate and adaptive arms of immune responses.
- Open Access
- 21 November 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (11) , e82929
Reciprocal Regulation of Development of Neutrophil-Dendritic Cell Hybrids in Mice by IL-4 and Interferon-Gamma
Neutrophils contribute to innate host immunity by functioning as professional phagocytes, whereas dendritic cells (DCs) are prototypic antigen presenting cells (APCs) responsible for the induction of adaptive immune responses. We have demonstrated recently that neutrophils trans-differentiate into a unique population, termed “neutrophil-DC hybrids,” expressing surface markers of both neutrophils and DCs and exhibiting dual functionality of both phagocytes and APCs. Although the hybrid cells emerged in significant numbers in murine bone marrow (BM) culture in the presence of GM-CSF, mechanisms regulating their development remained mostly unknown. In this study, we tested a total of 61 cytokines for their potentials to regulate neutrophil-DC hybrid formation using a newly developed BM micro-culture system combined with semi-automated FACS analysis. Several cytokines including GM-CSF were found to promote the generation of neutrophil-DC hybrids defined by the phenotype of CD11c+/MHC II+/Ly6G+. When tested in the presence of GM-CSF, hybrid cell development was enhanced by IL-4 and suppressed by interferon-γ (IFNγ) in dose-dependent fashions. We next determined in vivo impacts of IL-4 and IFNγ on the development of neutrophil-DC hybrids in thioglycollate-induced peritonitis lesions. Intraperitoneal administrations of IL-4/anti-IL-4 antibody complex (IL-4C) significantly increased the number of hybrids recovered from the lesions. By contract, recovery of hybrids was reduced by recombinant IFNγ. With regard to function, those hybrid cells recovered from IL-4C-treated mice and IFNγ-treated mice showed potent abilities to capture E.coli. These observations imply that emergence of neutrophil-DC hybrids in inflammatory sites is tightly regulated by local cytokine milieus.
- 21 November 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (11) , e82929
Open AccessReciprocal Regulation of Development of Neutrophil-Dendritic Cell Hybrids in Mice by IL-4 and Interferon-Gamma
Neutrophils contribute to innate host immunity by functioning as professional phagocytes, whereas dendritic cells (DCs) are prototypic antigen presenting cells (APCs) responsible for the induction of adaptive immune responses. We have demonstrated recently that neutrophils trans-differentiate into a unique population, termed “neutrophil-DC hybrids,” expressing surface markers of both neutrophils and DCs and exhibiting dual functionality of both phagocytes and APCs. Although the hybrid cells emerged in significant numbers in murine bone marrow (BM) culture in the presence of GM-CSF, mechanisms regulating their development remained mostly unknown. In this study, we tested a total of 61 cytokines for their potentials to regulate neutrophil-DC hybrid formation using a newly developed BM micro-culture system combined with semi-automated FACS analysis. Several cytokines including GM-CSF were found to promote the generation of neutrophil-DC hybrids defined by the phenotype of CD11c+/MHC II+/Ly6G+. When tested in the presence of GM-CSF, hybrid cell development was enhanced by IL-4 and suppressed by interferon-γ (IFNγ) in dose-dependent fashions. We next determined in vivo impacts of IL-4 and IFNγ on the development of neutrophil-DC hybrids in thioglycollate-induced peritonitis lesions. Intraperitoneal administrations of IL-4/anti-IL-4 antibody complex (IL-4C) significantly increased the number of hybrids recovered from the lesions. By contract, recovery of hybrids was reduced by recombinant IFNγ. With regard to function, those hybrid cells recovered from IL-4C-treated mice and IFNγ-treated mice showed potent abilities to capture E.coli. These observations imply that emergence of neutrophil-DC hybrids in inflammatory sites is tightly regulated by local cytokine milieus.
- 1 November 2012
- Published by Elsevier in Journal of Dermatological Science
- Vol. 68 (2) , 73-81
Development and validation of a new in vitro assay designed to measure contact allergen-triggered oxidative stress in dendritic cells
- 1 November 2012
- Published by Elsevier in Journal of Dermatological Science
- Vol. 68 (2) , 73-81
Development and validation of a new in vitro assay designed to measure contact allergen-triggered oxidative stress in dendritic cells
- Open Access
- 1 March 2012
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 132 (3) , 609-614
Real-Time Visualization of Macromolecule Uptake by Epidermal Langerhans Cells in Living Animals
- 1 March 2012
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 132 (3) , 609-614
Open AccessReal-Time Visualization of Macromolecule Uptake by Epidermal Langerhans Cells in Living Animals
- Open Access
- 1 June 2010
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 130 (6) , 1571-1580
Intravital Imaging of IL-1β Production in Skin
- 1 June 2010
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 130 (6) , 1571-1580
Open AccessIntravital Imaging of IL-1β Production in Skin
- Open Access
- 1 March 2010
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 120 (3) , 653-656
Bidirectional homing of Tregs between the skin and lymph nodes
Although several homing receptors are known to be differentially expressed by Tregs in lymphoid tissues compared with those found in peripheral tissues, it remains unclear whether these cells traffic between the two locations. In this issue of the JCI, Tomura et al. report steady-state Treg migration from the skin to draining LNs in mice. Furthermore, they report that not only does skin inflammation exacerbate LN-directed Treg homing, it also triggers reverse circulation of Tregs from LNs to skin, whereby these cells contribute to regulation of the immune response. These results now form a new framework for our understanding of Treg homing.
- 1 March 2010
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 120 (3) , 653-656
Open AccessBidirectional homing of Tregs between the skin and lymph nodes
Although several homing receptors are known to be differentially expressed by Tregs in lymphoid tissues compared with those found in peripheral tissues, it remains unclear whether these cells traffic between the two locations. In this issue of the JCI, Tomura et al. report steady-state Treg migration from the skin to draining LNs in mice. Furthermore, they report that not only does skin inflammation exacerbate LN-directed Treg homing, it also triggers reverse circulation of Tregs from LNs to skin, whereby these cells contribute to regulation of the immune response. These results now form a new framework for our understanding of Treg homing.
- Open Access
- 1 December 2009
- Published by Wiley in European Journal of Immunology
- Vol. 39 (12) , 3331-3342
IL‐33 promotes DC development in BM culture by triggering GM‐CSF production
Short‐term DC cultures generated with GM‐CSF and other cytokines have markedly improved our ability to study the immunobiology of DC. Here, we tested 65 cytokines individually for their potential to promote the generation of CD11c+ cells in a murine BM culture system. In addition to several cytokines known to promote DC survival and/or growth, IL‐33 was found to augment DC development time‐ and dose‐dependently. Although the resulting CD11c+ cells generated in the presence of IL‐33 exhibited a typical dendritic morphology, they expressed MHC class II molecules only at modest levels, showed negligible responses to TLR ligands, produced no detectable IL‐12 p70, displayed PD‐L1 and PD‐L2 on the surface, and failed to activate immunologically naïve T cells efficiently. IL‐33‐induced expansion of CD11c+ cells was completely blocked by anti‐GM‐CSF mAb, and GM‐CSF mRNA and protein expression in BM culture was markedly elevated by added IL‐33, indicating that IL‐33 promotes in vitro DC generation indirectly by a GM‐CSF‐dependent manner. With regard to the cellular source, IL‐33‐dependent GM‐CSF production was observed exclusively within the CD45+/FcεRI+ BM population. Not only do our results reinforce the notion that GM‐CSF serves as a primary DC growth factor, but they also reveal a previously unrecognized mechanism supporting DC development.
- 1 December 2009
- Published by Wiley in European Journal of Immunology
- Vol. 39 (12) , 3331-3342
Open AccessIL‐33 promotes DC development in BM culture by triggering GM‐CSF production
Short‐term DC cultures generated with GM‐CSF and other cytokines have markedly improved our ability to study the immunobiology of DC. Here, we tested 65 cytokines individually for their potential to promote the generation of CD11c+ cells in a murine BM culture system. In addition to several cytokines known to promote DC survival and/or growth, IL‐33 was found to augment DC development time‐ and dose‐dependently. Although the resulting CD11c+ cells generated in the presence of IL‐33 exhibited a typical dendritic morphology, they expressed MHC class II molecules only at modest levels, showed negligible responses to TLR ligands, produced no detectable IL‐12 p70, displayed PD‐L1 and PD‐L2 on the surface, and failed to activate immunologically naïve T cells efficiently. IL‐33‐induced expansion of CD11c+ cells was completely blocked by anti‐GM‐CSF mAb, and GM‐CSF mRNA and protein expression in BM culture was markedly elevated by added IL‐33, indicating that IL‐33 promotes in vitro DC generation indirectly by a GM‐CSF‐dependent manner. With regard to the cellular source, IL‐33‐dependent GM‐CSF production was observed exclusively within the CD45+/FcεRI+ BM population. Not only do our results reinforce the notion that GM‐CSF serves as a primary DC growth factor, but they also reveal a previously unrecognized mechanism supporting DC development.
- Open Access
- 31 August 2009
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (17) , 6987-6994
Dual Therapeutic Efficacy of Vinblastine as a Unique Chemotherapeutic Agent Capable of Inducing Dendritic Cell Maturation
Our recent unbiased functional screen of 54 chemotherapeutic drugs unveiled striking heterogeneity in their effects on dendritic cells (DC). Most notably, vinblastine (VBL) was found to induce phenotypic and functional maturation of DCs in vitro. Here, we sought to determine whether VBL exhibits “dual” therapeutic efficacy in living animals by directly killing tumor cells and by boosting host immunity via DC maturation. Local injection of VBL in a low dose into the skin of C57BL/6 mice induced in situ maturation of epidermal Langerhans cells. When coinjected with a model antigen, ovalbumin (OVA), VBL enhanced OVA-specific cellular and humoral immune responses. When injected directly into the OVA cDNA–transduced E.G7 tumors, VBL augmented clonal expansion of OVA-reactive CD8 T cells and CTL activities. In B16 melanoma model, intratumor VBL injection induced apoptosis of melanoma cells, phenotypic maturation of tumor-infiltrating DCs, and significant CTL activities. Although complete clearance was never achieved, growth kinetic of B16 melanoma was markedly reduced in C57BL/6 mice by intratumor VBL injection. Importantly, the same treatment was far less efficacious in immunocompromised severe combined immunodeficient mice, indicating the requirement of intact host immunity. Our results introduce a new concept that VBL may be used to design “immunostimulatory” chemotherapy regimens. [Cancer Res 2009;69(17):6987–94]
- 31 August 2009
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (17) , 6987-6994
Open AccessDual Therapeutic Efficacy of Vinblastine as a Unique Chemotherapeutic Agent Capable of Inducing Dendritic Cell Maturation
Our recent unbiased functional screen of 54 chemotherapeutic drugs unveiled striking heterogeneity in their effects on dendritic cells (DC). Most notably, vinblastine (VBL) was found to induce phenotypic and functional maturation of DCs in vitro. Here, we sought to determine whether VBL exhibits “dual” therapeutic efficacy in living animals by directly killing tumor cells and by boosting host immunity via DC maturation. Local injection of VBL in a low dose into the skin of C57BL/6 mice induced in situ maturation of epidermal Langerhans cells. When coinjected with a model antigen, ovalbumin (OVA), VBL enhanced OVA-specific cellular and humoral immune responses. When injected directly into the OVA cDNA–transduced E.G7 tumors, VBL augmented clonal expansion of OVA-reactive CD8 T cells and CTL activities. In B16 melanoma model, intratumor VBL injection induced apoptosis of melanoma cells, phenotypic maturation of tumor-infiltrating DCs, and significant CTL activities. Although complete clearance was never achieved, growth kinetic of B16 melanoma was markedly reduced in C57BL/6 mice by intratumor VBL injection. Importantly, the same treatment was far less efficacious in immunocompromised severe combined immunodeficient mice, indicating the requirement of intact host immunity. Our results introduce a new concept that VBL may be used to design “immunostimulatory” chemotherapy regimens. [Cancer Res 2009;69(17):6987–94]
- 31 August 2009
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (17) , 6978-6986
Classification of Chemotherapeutic Agents Based on Their DifferentialIn vitroEffects on Dendritic Cells
Despite the crucial roles dendritic cells (DC) play in host immunity against cancer, the pharmacologic effects of many chemotherapeutic agents have remained mostly unknown. We recently developed a DC biosensor clone by engineering the stable murine DC line XS106 to express the yellow fluorescent protein (YFP) gene under the control of interleukin (IL)-1β promoter. In this study, the resulting XS106 pIL1-YFP DC clone was used to screen 54 anticancer drugs. Each drug was tested at five concentrations (0.1–10 μmol/L) for its effects on YFP expression, cell viability, and granulocyte macrophage colony-stimulating factor–dependent growth. Our unbiased systematic screening unveiled a striking heterogeneity among the tested anticancer drugs in their effects on the three functional variables. Interestingly, 15 drugs induced significant YFP expression at subcytotoxic concentrations and were thus categorized as “DC-stimulatory” anticancer drugs. These drugs were subsequently found to induce at least one of the characteristic maturational changes in mouse bone marrow–derived DCs. For example, vinblastine, a prototypic drug of this class, induced the production of IL-1β, IL-6, and IL-12, increased surface expression of CD40, CD80, CD86, and MHC class II, and augmented T cell–stimulatory capacity of DCs. Not only do these results illustrate the differential pharmacologic effects of commonly used chemotherapeutic agents on DCs, they may also provide a conceptual framework for rationale-based selection and combination of anticancer drugs for clinical application. [Cancer Res 2009;69(17):6978–86]
- 31 August 2009
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (17) , 6978-6986
Classification of Chemotherapeutic Agents Based on Their DifferentialIn vitroEffects on Dendritic Cells
Despite the crucial roles dendritic cells (DC) play in host immunity against cancer, the pharmacologic effects of many chemotherapeutic agents have remained mostly unknown. We recently developed a DC biosensor clone by engineering the stable murine DC line XS106 to express the yellow fluorescent protein (YFP) gene under the control of interleukin (IL)-1β promoter. In this study, the resulting XS106 pIL1-YFP DC clone was used to screen 54 anticancer drugs. Each drug was tested at five concentrations (0.1–10 μmol/L) for its effects on YFP expression, cell viability, and granulocyte macrophage colony-stimulating factor–dependent growth. Our unbiased systematic screening unveiled a striking heterogeneity among the tested anticancer drugs in their effects on the three functional variables. Interestingly, 15 drugs induced significant YFP expression at subcytotoxic concentrations and were thus categorized as “DC-stimulatory” anticancer drugs. These drugs were subsequently found to induce at least one of the characteristic maturational changes in mouse bone marrow–derived DCs. For example, vinblastine, a prototypic drug of this class, induced the production of IL-1β, IL-6, and IL-12, increased surface expression of CD40, CD80, CD86, and MHC class II, and augmented T cell–stimulatory capacity of DCs. Not only do these results illustrate the differential pharmacologic effects of commonly used chemotherapeutic agents on DCs, they may also provide a conceptual framework for rationale-based selection and combination of anticancer drugs for clinical application. [Cancer Res 2009;69(17):6978–86]